logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 11 of 11 Items
Showing 1 - 11 of 11 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Conference Material
|
Abstract

Once-weekly repurposed fosravuconazole versus daily itraconazole, with surgery, in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial

Fahal AH, Ahmed ES, Bakhiet SM, Bakheet OE, Fahal LA,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
INTRODUCTION
Treatment options for the highly neglected fungal tropical disease eumycetoma are limited and poorly adapted to patients’ contexts, with surgery often required. The firs...
Conference Material
|
Slide Presentation

Once-weekly repurposed fosravuconazole versus daily itraconazole, with surgery, in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial

Fahal AH, Ahmed ES, Bakhiet SM, Bakheet OE, Fahal LA,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Journal Article
|
Review

Vaccines and therapeutics for immunocompromised patients with COVID-19

Shoham S, Batista C, Ben Amor Y, Ergonul O, Hassanain M,  et al.
2023-05-01 • eClinicalMedicine
2023-05-01 • eClinicalMedicine
The COVID-19 pandemic has disproportionately impacted immunocompromised patients. This diverse group is at increased risk for impaired vaccine responses, progression to severe disease, p...
Journal Article
|
Commentary

Urgent needs to accelerate the race for COVID-19 therapeutics

Batista C, Shoham S, Ergonul O, Hotez PJ, Bottazzi ME,  et al.
2021-06-01 • eClinicalMedicine
2021-06-01 • eClinicalMedicine
Journal Article
|
Research

Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India

Goyal V, Mahajan R, Pandey K, Singh SN, Singh RS,  et al.
2018-10-22 • PLOS Neglected Tropical Diseases
2018-10-22 • PLOS Neglected Tropical Diseases
BACKGROUND
In 2010, WHO recommended the use of new short-course treatment regimens in kala-azar elimination efforts for the Indian subcontinent. Although phase 3 studies have shown e...
Journal Article
|
Research

The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment

Pedrique B, Strub-Wourgaft N, Some C, Olliaro PL, Trouiller P,  et al.
2013-12-01 • Lancet Global Health
2013-12-01 • Lancet Global Health
In 1975-99, only 1·1% of new therapeutic products had been developed for neglected diseases. Since then, several public and private initiatives have attempted to mitigate this imbalance....
Journal Article
|
Commentary

Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment

Naniche D, Hotez PJ, Bottazzi ME, Ergonul O, Figueroa J,  et al.
2021-06-01 • eClinicalMedicine
2021-06-01 • eClinicalMedicine
Journal Article
|
Research

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia

Diro EGJ, Blesson S, Edwards T, Koert R, Ritmeijer KKD,  et al.
2019-01-17 • PLOS Neglected Tropical Diseases
2019-01-17 • PLOS Neglected Tropical Diseases
BACKGROUND
Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by...
Journal Article
|
Commentary

Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic

Hotez PJ, Batista C, Amor YB, Ergonul O, Figueroa J,  et al.
2021-08-03 • eClinicalMedicine
2021-08-03 • eClinicalMedicine
A Lancet Commission for COVID-19 task force is shaping recommendations to achieve vaccine and therapeutics access, justice, and equity. This includes ensuring safety and effectiveness ha...
Journal Article
|
Research

Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India

Goyal V, Burza S, Pandey K, Singh SN, Singh RS,  et al.
2019-09-26 • PLOS Neglected Tropical Diseases
2019-09-26 • PLOS Neglected Tropical Diseases
BACKGROUND:
An earlier open label, prospective, non-randomized, non-comparative, multi-centric study conducted within public health facilities in Bihar, India (CTRI/2012/08/002891) ...
Journal Article
|
Commentary

The silent and dangerous inequity around access to COVID-19 testing: A call to action

Batista C, Hotez PJ, Ben Amor Y, Kim JH, Kaslow D,  et al.
2022-01-01 • eClinicalMedicine
2022-01-01 • eClinicalMedicine